Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.

@article{Owens2016PreclinicalPA,
  title={Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.},
  author={Christopher M Owens and Bradley B Brasher and Alex Polemeropoulos and Michael H J Rhodin and Nicole McAllister and Xiaowen Peng and Ce Wang and Lu Ying and Hui Cao and Eric J. Lawitz and Fred F Poordad and Juan Carlos Rondon and Terry D. Box and Stefan Zeuzem and Peter Buggisch and Kai Cheng Lin and Y Qiu and Lijuan Jiang and Richard A. Colvin and Yat Sun Or},
  journal={Antimicrobial agents and chemotherapy},
  year={2016},
  volume={60 10},
  pages={6207-15}
}
EDP-239, a novel hepatitis C virus (HCV) inhibitor targeting nonstructural protein 5A (NS5A), has been investigated in vitro and in vivo EDP-239 is a potent, selective inhibitor with potency at picomolar to nanomolar concentrations against HCV genotypes 1 through 6. In the presence of human serum, the potency of EDP-239 was reduced by less than 4-fold. EDP-239 is additive to synergistic with other direct-acting antivirals (DAAs) or host-targeted antivirals (HTAs) in blocking HCV replication and… CONTINUE READING

From This Paper

Topics from this paper.
1 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…